Products

Colorectal IHC portfolio

VENTANA MMR IHC Panel

Deliver diagnostic confidence 


Multiple guidelines, including NCCN, ASCO, EGAPP, and NICE,1-4 recommend universal screening of all newly diagnosed colorectal cancers for Lynch syndrome with the intent to prevent cancers and save lives.5 The VENTANA MMR IHC Panel class II IVD consists of VENTANA anti-MLH1 (M1), VENTANA anti-PMS2 (A16-4), VENTANA anti-MSH2 (G219-1129), VENTANA anti-MSH6 (SP93, and VENTANA BRAF V600E (VE1), and aids in identification of patients at risk for Lynch syndrome in patients diagnosed with colorectal cancer (CRC). 

 

The inclusion of the exclusive VENTANA BRAF V600E (VE1) antibody helps refine the number of patients who receive additional testing for Lynch syndrome by aiding in the identification of sporadic CRC in the absence of MLH1 expression.6  

 

The ready-to-use VENTANA MMR IHC Panel is optimized for use with the OptiView DAB IHC Detection Kit and ancillaries on the fully-automated BenchMark ULTRA instrument. 

algorithm
VENTANA anti-MLH1 (M1) Mouse Monoclonal Primary Antibody
MLH-1-(M1)
VENTANA anti-PMS2 (A16-4) Mouse Monoclonal Primary Antibody
PMS2 (A16-4)
VENTANA anti-MSH2 (G219-1129) Mouse Monoclonal Primary
Antibody
MSH2 (G219-1129)
VENTANA anti-MSH6 (SP93) Rabbit Monoclonal Primary Antibody 
MSH6 (SP93)
VENTANA anti-BRAF V600E (VE1) Mouse Monoclonal Primary Antibody
BRAF V600E (VE1)

Resources  / 

References:

1. NCCN Guidelines Version 1.2017. Genetic/Familial High Risk Assessment: Colorectal. NCCN Clinical Practice Guideline in Oncology. NCCN.org.

2. Evaluation of Genomic Applications in Practice and Prevention Working Group. (2009). Recommendations from the EGAPP working group: genetic testing strategies in thenewly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genetics in Medicine, 11(1), 35–41.

3. ASCO, A.C.A, 2016. Guideline on the Evaluation of Molecular Markersfor ColorectalCancer Expert Panel Draft Recommendations Summary for Open CommentPeriodAmerican Society for Clinical Pathology, the College of AmericanPathologists. the Association for Molecular Pathology, and the American Society of Clinical Oncology<http://www.amp.org/committees/clinicalpractice/documents/20150327CRCMMDraftRecommendationsforOCP-UPDATEDfinaldraft 001.pdf>.

4. NICE, 2017. Molecular Testing Strategies for Lynch Syndrome in People with Colorectal Cancer. National Institute for Health and Care Excellence. http://www.nice.org.uk/guidance/dg27/chapter/1-Recommendations.

5. Hampel H: Genetic counseling and cascade genetic testing in Lynch syndrome. Fam Cancer 15:423-427, 2016

6. Roth, R. M. et al. A modified Lynch syndrome screening algorithm in colon cancer: BRAF immunohistochemistry is efficacious and cost beneficial. Am. J. Clin. Pathol. 143,336–343 (2015

Filter